OUR RESEARCH

Active ITOG Sponsored Clinical Trials

Advancing innovation in thyroid oncology requires collaboration, transparency, and access to clinical research worldwide. The International Thyroid Oncology Group (ITOG) is committed to supporting physicians, researchers, and patients by providing access to ongoing global clinical trials in thyroid cancer. ITOG designs and conducts collaborative, multicenter clinical trials to improve outcomes for patients with thyroid cancer.

ITOG SPONSORED

Current Trials

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer >

  • Accrual Status: Closed to Accrual

  • Accrual Goal:
  • Current Accrual:

Principal Investigator: Mark Zafereo, MD
MD Anderson Cancer Center

OSU 17277: A Phase 1 Trial of concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinb in BRAF Mutated Anaplastic or Poorly Differentiated Thyroid Cancer >

  • Accrual Status: Accruing

  • Accrual Goal:
  • Current Accrual:

Principal Investigator: Terrence Williams
City of Hope

Upcoming Trials

XL092-IST213: Neoadjuvant treatment with XL092 for advanced thyroid cancer

Mark Zafereo and Greg Randolph

Neoadjuvant BRAF WT ATC

Sid Sheth/Exelixis and Regeneron

Dabrafenib/Trametinib versus placebo for high risk BRAF MUT thyroid cancer

Alan Ho, Alliance

BRAF-HER3 Alliance Study

Eric Sherman, Boeher

ITOG SPONSORED

Past Trials

NCI 10240: Phase II Study of Cabozantinib in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after 1 Prior VEGFR-Targeted Therapy >

  • Accrual Status: Closed to Accrual

Ohio State University
University of Pittsburgh
University of Kentucky
City of Hope
Moffitt
Mayo Clinic Rochester

Sponsors: CTEP/NCI, ITOG
Coordinating organization: The Ohio State University

Principal Investigator: Bhavana Konda, MD; The Ohio State University

ACCRU/ITOG 1504 Combination Immunotherapy with Multikinase Inhibitor (MKI) in Progressive, Radiodine-resistant Differentiated Thyroid Cancers >

  • Accrual Status: Closed to Accrual as of April 1, 2020
  • Accrual Goal: 60
  • Current Accrual: 60
  • Sponsors: Eisai/Merck
  • Coordinating Organization: ACCRU

Cohort 1:30 / Cohort 2: 27 (Updated 4/1/2020)

University of Michigan 12
University of Colorado 11
Dana-Farber/Harvard CC 9
Ohio State University 6
Memorial Sloan Kettering 7
UCLA Medical Center 5
MD Anderson 7
Total 57

Principal Investigator: Bryan Haugen, MD at University of Colorado Medical Center
Co-Principal Investigator: Lori Wirth, MD
Publication/Presentation Status: Pending
***Status Change March 26, 2019 – Cohort 1 is permanently closed to patient accrual per protocol as of March 26, 2019.

Selumetinib plus RAI for RAI-Avid Thyroid Cancers >

  • Accrual Status: Closed to Accrual
  • Accrual Goal: 60
  • Current Accrual: 60
  • Sponsor: Astrazeneca
  • Coordinating Organization: ACCRU

ACCRU Dashboard December 2019

Principal Investigator: Alan Ho, MD at Memorial Sloan-Kettering Cancer Center
Co-PI: Mabel Ryder, MD
Publication/Presentation Status: Pending

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) >

  • Accrual Status: Accruing
  • Sponsor: Loxo-Oncology
  • Coordinating Organization: LOXO-Oncology

Leader at ITOG: Lori Wirth and ITOG protocol-specific steering committee
Publication Status: Pending (N Engl J Med 2020, 383:825-835; August 27, 2020)
Presentations: ASCO Jun 2018, ATA Oct 2018

ALLIANCE A091302 >

Randomized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer (PI- Dr. E. Sherman); Alliance study,

  • Target Accrual Goal: 30
  • Accrued to Date: 30
  • Accrual Status: Permanently Closed

Principal Investigator: Eric Sherman, MD Memorial-Sloan Kettering Cancer Center
Publication: Pending

Presentation: ASCO 2021

An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) >

  • Accrual Status: Terminated
  • Sponsor: Eisai
  • Coordinating Organization: Eisai

Leader at ITOG: Lori Wirth and ITOG protocol-specific steering committee
Publication/Presentation: ENDO JUNE 2020 Status: Pending

Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy >

  • Accrual Status: Permanently Closed
  • Accrual Goal: 25
  • Current Goal: 25
  • Sponsors: CTEP/NCI, ITOG
  • Coordinating Organization: ACCRU

Principal Investigator: Manisha Shah, MD at The Ohio State University
Co-PI: Maria Cabanillas, MD
Publication Status: Published Journal of Clinical Oncology – Oct 2017 JCO.2017.73.0226
Presentations: ASCO Annual Meeting Jun 2017, National Cancer Institute CTEP Cabozantinib Investigators Meeting (2015, 2017), 15th International Thyroid Congress (Oct 2015).

Discover the Full Scope of ITOG Research